A retrospective study on risk factors affecting liver function with clozapine
Not Applicable
- Conditions
- treatment-resistant schizophrenia
- Registration Number
- JPRN-UMIN000050407
- Lead Sponsor
- ational Center of Neurology and Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Those who with defective data 2) Those who are receiving hepatic function-improving drugs prior to taking clozapine 3) Those who have elevated levels of liver enzymes prior to taking clozapine
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative dose of clozapine at 4, 8, 12, 16, and 18 weeks
- Secondary Outcome Measures
Name Time Method Sex,BMI,age, concomitant medications,etc